Amryt Pharma plc

11.83+0.1400+1.20%Vol 26.81K1Y Perf 4.62%
Jun 14th, 2021 16:00 DELAYED
BID11.64 ASK11.84
Open11.75 Previous Close11.69
Pre-Market- After-Market-
 - -  - -%
Target Price
37.33 
Analyst Rating
— — 0.00
Potential %
215.55 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     34.21
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.03
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap424.42M 
Earnings Rating
Price Range Ratio 52W %
32.54 
Earnings Date
5th Aug 2021

Today's Price Range

11.6112.00

52W Range

10.0615.50

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
0.85%
1 Month
6.87%
3 Months
-17.85%
6 Months
-10.72%
1 Year
4.62%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AMYT11.830.14001.20
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Financial StrengthValueIndustryS&P 500US Markets
1.30
2.10
0.78
3.51
-1.70
Leverage Ratio 7.40
ProfitabilityValueIndustryS&P 500US Markets
41.10
-31.00
-7.30
-225.50
-49.00
RevenueValueIndustryS&P 500US Markets
167.15M
4.66
129.06
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.09-
Q03 2020--0.07-
Q02 2020--0.12-
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th Aug 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume26.81K
Shares Outstanding35.88M
Trades Count325
Dollar Volume138.93K
Avg. Volume48.81K
Avg. Weekly Volume49.99K
Avg. Monthly Volume77.19K
Avg. Quarterly Volume70.63K

Amryt Pharma plc (NASDAQ: AMYT) stock closed at 11.83 per share at the end of the most recent trading day (a 1.2% change compared to the prior day closing price) with a volume of 26.81K shares and market capitalization of 424.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 88 people. Amryt Pharma plc CEO is Joseph Amrit Wiley.

The one-year performance of Amryt Pharma plc stock is 4.62%, while year-to-date (YTD) performance is -16.45%. AMYT stock has a five-year performance of %. Its 52-week range is between 10.06 and 15.5, which gives AMYT stock a 52-week price range ratio of 32.54%

Amryt Pharma plc currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 7.71, a price-to-sale (PS) ratio of 2.54, a price to cashflow ratio of 16.40, a PEG ratio of 2.32, a ROA of -17.18%, a ROC of -27.41% and a ROE of -113.81%. The company’s profit margin is -49.00%, its EBITDA margin is -7.30%, and its revenue ttm is $167.15 Million , which makes it $4.66 revenue per share.

Of the last four earnings reports from Amryt Pharma plc, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Amryt Pharma plc’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Amryt Pharma plc is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Amryt Pharma plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amryt Pharma plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amryt Pharma plc has a Sell technical analysis rating based on Technical Indicators (ADX : 39.87, ATR14 : 0.48, CCI20 : 7.65, Chaikin Money Flow : -0.26, MACD : -0.18, Money Flow Index : 44.40, ROC : -0.26, RSI : 45.83, STOCH (14,3) : 41.35, STOCH RSI : 0.88, UO : 40.72, Williams %R : -58.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amryt Pharma plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Amryt Pharma plc

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

CEO: Joseph Amrit Wiley

Telephone: +44 2030267257

Address: 196 High Road, London N22 8HH, , GB

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

News

Stocktwits